The diagram shows the pilot's environment in the Gossamer Albatross, a plane designed to cross the Manche between England and France. The upright seat position was favored by the cyclist-pilot for ...

In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 and attract ...

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

GOSSAMER BIO ($GOSS) is expected to release its quarterly earnings data on Friday, March 21st after market close, per Finnhub. Analysts are expecting revenue of ...

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

Gossamer Bio has a one year low of $0.50 and a one year high of $1.60. The stock has a market cap of $278.72 million, a PE ratio of -3.84 and a beta of 1.81. The firm has a 50 day simple moving ...